Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Gilead avoids billions in U.S. taxes on its $1,000-a-pill drug

    Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas.

    27 February 2015 | Chicago Tribune
  • HIV and LGTB NGOs and other concerned actors across Europe call for futher action on pre-exposure prophylaxis

    The European AIDS Treatment Group (EATG), Europe’s network of HIV activists, and  AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV LGBT civil society organisations and concerned actors, issued an urgent HIV Prevention Manifesto today. We demand that pre-exposure prophylaxis for HIV (PrEP) is made available as soon as possible within the European Union, and that Gilead, the company that makes the PrEP medicine Truvada®, submits an application to the European Medicines Agency (EMA) for a change of indication so that its use to prevent HIV can be approved.

    25 February 2015 | EATG
  • Merck places children's HIV drug in shared non-profit patent pool

    U.S. drugmaker Merck & Co has contributed an HIV medicine for children to an international shared patent pool in a move that should speed the development of cheap pediatric formulations for use in poor countries.

    24 February 2015 | Reuters
  • amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

    The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.

    19 February 2015 | amfAR
  • The Drug That Is Bankrupting America

    With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.

    18 February 2015 | Huffington Post
  • Patient groups rank ViiV Healthcare #1 in corporate reputation survey, again

    PatientView surveyed 1,150 patient groups from 58 countries and asked them about the corporate reputation of 37 pharma companies. The respondents ranked ViiV Healthcare number one across the board. Gilead fell from the #2 ranking position in 2013 to #14 in 2014—likely a consequence of the controversially high prices for specialty hep C meds.

    16 February 2015 | Bio Pharma Dive
  • How ViiV Healthcare became a pharma favorite for patient groups

    Earlier this week, PatientView published the results of its country survey, which asked more than 1,000 global patient groups to rank biopharmaceutical companies based on their overall "corporate reputation." For the second year in a row, ViiV Healthcare, a joint venture between Pfizer, GlaxoSmithKline, and Shionogi and headquartered in the U.K. (which may also have the biggest IPO for a pharma company ever later this year), emerged as number one.

    16 February 2015 | BioPharma Dive
  • Healthcare: The race to cure rising drug costs

    The controversy over hepatitis C drug prices has highlighted the broader question of whether pharmaceutical companies can defend their premium pricing model in the world’s biggest healthcare market. It is a battle that big pharma risks losing, raising questions over the economic model of an industry that relies heavily on US profits to reward investors and finance new drugs.

    13 February 2015 | Financial Times
  • FDA revokes breakthrough status for BMS hep C drug

    The big biotech tells FierceBiotech in a statement that the agency has "informed Bristol-Myers Squibb that, due to the evolving HCV treatment landscape, the agency intends to rescind the breakthrough therapy designation for certain genotype 1 hepatitis C regimens related to daclatasvir." Bristol-Myers then went on to add that the decision will not impact its timetable on an NDA for daclatasvir, which faces a unique set of challenges all its own.

    11 February 2015 | Fierce Biotech
  • Dutrebis, New HIV Drug, Approved by FDA, but Not Commercially Available

    The new combination contains 150 mg of lamivudine (3TC, Epivir) and 300 mg of raltegravir (Isentress). Despite the FDA approval, the drug manufacturer, Merck Pharmaceuticals, announced that they would not be making Dutrebis commercially available in the U.S. at this time.

    11 February 2015 | The Body Pro
More news


Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.